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Abstract
The Plasmodium vivax Duffy Binding Protein (DBP) is the ligand in the major
pathway for P. vivax invasion of human reticulocytes, making it an appealing
vaccine candidate. Region II of DBP (DBP-RII) is the minimal portion of the
ligand that mediates recognition of the Duffy Antigen Receptor for Chemokines
(DARC receptor) on the reticulocyte surface and constitutes the primary vaccine
target. Analysis of natural variation in the coding sequences of DBP-RII revealed
signature evidence for selective pressure driving variation in the residues of the
putative receptor-binding site. We hypothesize that anti-DBP immunity in P. vivax
infections is strain-specific and hindered by polymorphic residues altering
sensitivity to immune antibody inhibition.

To comprehend the human IgG

response following P. vivax infections we investigated the specificity of IgG in
Pursat Province, Western Cambodia. Using ELISAs, we quantified the antibody
titer against five variant alleles of DBP-RII. We also sequenced the DBP-RII of
the field isolates to determine their relationship to the variant alleles used in the
ELISAs.

When correlating the IgG titer between the DBP variants a strain-

specific immune response was observed in patients with a high antibody titer to
DBP-RII_AH as compared to the other variants. This was different from the
correlation of high antibody titers between DBP-RII_P and DBP-RII_7.18
(ρ=0.88,

p-value<0.0001)

and

DBP-RII_P

and

DBP-RII_O

(ρ=0.87,

pvi

value<0.0001).

There appeared to be little correlation between specific

polymorphic residues and IgG titer. Understanding the immune response to the
polymorphisms within PvDBP will allow further identification of epitopes to enable
the production of a more effective P. vivax vaccine.

vii

Literature Review
1.0 Malaria Worldwide
Malaria is one of the most widespread vector-borne illnesses to plague the
world.

According to a report presented by the WHO that surveyed over 106

malaria endemic countries, in 2009 there were an estimated 225 million cases of
malaria with an estimated 800,000 fatalities in 2010 (WHO, 2010a).

Malaria is

caused by the Plasmodium parasite being transmitted through the saliva of. The
five human Plasmodium parasites require both mosquito and a human host to
survive.

Although control and elimination of malaria infections has been

achieved in numerous countries, plans for worldwide eradication of the disease
has been met with multiple obstacles.

Increasing drug-resistance among

parasites has made it difficult for healthcare providers to effectively treat
infections and has been increasing the cost of treatment in already impoverished
regions. Also, due to the parasites ability to evade the human host’s immune
system, production of a malaria vaccine that addresses all variants parasites has
eluded researchers. This has results in current efforts to minimize infections
through vector control and controlling drug-resistance as much as possible.
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2.0 Malaria Life Cycle
The five species of malaria found to infect humans are Plasmodium
falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and
Plasmodium knowlesi (Vythilingam et al., 2006).

Although Plasmodium

falciparum is known to cause the most severe disease and is highly prevalent in
Africa, Plasmodium vivax (P. vivax), causing a milder form of malaria in many
cases, is thought to account for nearly 56% of non-African malarial infections
worldwide (K. Mendis, Sina, Marchesini, & Carter, 2001). P. vivax has a 48 hour
life cycle in humans (Figure 1), starting from inoculation of sporozoites to
gametocyte production (Karunaweera, Grau, Gamage, Carter, & K. N. Mendis,
1992).
humans.

P. vivax parasites undergo liver stage and an erythrocytic stage in
During the liver stage sporozoites infect hepatocytes and produce

schizonts, which rupture the cell and release merozoites. In P. vivax, merozoites
are carried to the circulatory system where they invade reticulocytes and begin
the erythrocytic stage. During this stage schizonts mature to form trophozoties,
which will either mature into gametocytes and be transmitted to Anopheles
mosquitoes during a blood meal, or will mature into schizonts, rupture the cell,
and merozoites infect nearby reticulocytes (T. J. Hadley, Klotz, & Louis H. Miller,
1986). Since human adult blood contains approximately 1% reticulocytes, the
parasitemia for P. vivax infections is usually much lower than that of P.
falciparum (T. J. Hadley, Klotz, & Louis H. Miller, 1986) .

2

Figure 1: Plasmodium Life Cycle. The general life cycle for human Plasmodium species, as
provided by Hadley et al. The erythrocytic cycle (boxed), including merozoite invasion, is the
focus of this study.
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3.0 P. vivax Invasion
3.1 Invasion Pathway. The only known pathway for P.vivax invasion is via
erythrocyte binding by the Duffy Bind Protein (DBP) (Figure 2). DBP is housed in
the microneme of merozoites and released to the parasite surface during
invasion (M Aikawa, L H Miller, Johnson, & Rabbege, 1978; Ladda, Masamichi
Aikawa, & Sprinz, 1969). The merozoite attaches to the host reticulocyte and
undergoes reorientation to position the apical end on the erythrocyte, deforming
the erythrocyte (M Aikawa et al., 1978; Ladda et al., 1969). At this point, DBP is
released from the microneme and facilitates the engulfing of the parasite into the
parasitophorous vacuole (VanBuskirk, Sevova, & John H Adams, 2004) .

4

Figure 2: P. vivax Merozoite Invasion. Image provided in Beeson et al. (A) The P. vivax
merozoite attaches to the reticulocyte surface and undergoes reorientation. DBP is released tot
eh surface of the merozoite and facilitates parasite invasion. (B)The interaction between the DBP
ligand region II and the DARC blood group antigen on the surface of the erythrocyte allow the
parasite to invade (J.G. Beeson & Crabb, 2007).
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DBP is a large, seven region transmembrane protein, with region II and
region IV being the most cystine-rich, meaning their function depends on proper
conformations (VanBuskirk, Sevova, & John H Adams, 2004). The Duffy binding
like (DBL) domain binds to the Duffy antigen/receptor for chemokines (DARC) on
the surface of the Duffy blood group antigen on the host cell and allows the
merozoite to be engulfed in the parasitophorous vacuole, where it progresses to
a trophozoite (Hadley, Klotz, & Louis H. Miller, 1986; Grimberg et al., 2007). As
the preferred method of invasion, it is generally accepted that only person with
the Duffy blood group antigen are able to contract P. vivax infections (T. J.
Hadley, Klotz, & Louis H. Miller, 1986; Horuk et al., 1993).
3.2 Immune System Complications. Since the DBP/DARC interaction is
the most important pathway for P. vivax invasion, DBP is presented as a viable
vaccine target.

Removal of the Duffy blood group antigens by treating the

erythrocyte with chymotryspin prohibits P. vivax invasion (A. P. Singh et al.,
2005) . However, a DBP vaccine has been difficult to procure for two reasons.
First, DBP is released very quickly during invasion, leaving is small window of
opportunity for antibody production (VanBuskirk, Sevova, & John H Adams,
2004). Second, antibodies created to DBP don’t confer lasting immunity to P.
vivax infections due the multitude of polymorphic residues found throughout
DBPII, contains the binding site for invasion (C.E. Chitnis & L.H. Miller, 1994;
Ranjan & C.E. Chitnis, 1999). The polymorphic residues create variant strains of
P. vivax due to pressure from the immune system. These residues also tend to
6

be located near epitopes essential for DBP binding to erythrocytes and can
misdirect the host’s immune system (Chootong et al., 2010; VanBuskirk, Sevova,
& John H Adams, 2004).

Antibodies to variant strains are made to these

polymorphic residues instead of the conserved residues essential for erythrocyte
binding (Chootong et al., 2010; VanBuskirk, Sevova, & J. H. Adams, 2004; K.
Mendis et al., 2001). This may limit the cross-reactivity of antibodies between
variants.
3.3 Vaccine Development Complications. One of the vaccine strategies
that has emerged to overcome these obstacles; a combination vaccine that
includes highly immunogenic and cross-reactive DBP variants (M ArévaloHerrera & S Herrera, 2001; Sócrates Herrera, Corradin, & Myriam ArévaloHerrera, 2007). However, the immune response to variant DBP alleles is not
fully understood; therefore it is unclear which DBP allele is the most
immunogenic and can provide the most cross-reactive immune response
possible.

Also, antibodies to DBP provide only short-term immunity to vivax

infections (K. Mendis et al., 2001). Furthermore, the number of DBP variants and
their distribution from region to region is also unknown.

It’s unknown if a

combination vaccine would need to be specialized by region or modified from
year to year.
Along with multiple variant alleles of DBP, P. vivax exposure varies across
the world.

For example, inhabitants of Papua New Guinea (PNG), a highly

endemic region, are constantly exposed to P. vivax and have been known to
7

acquire some form of immunity or asymptomatic infection as they age (Cattani et
al., 1986; Xainli et al., 2002). By contrast, inhabitants of a low endemic region,
for example Cambodia, are less likely to have constant exposure to P. vivax;
therefore, would have very little immunity and would become ill from a P. vivax
infection (Luxemburger et al., 1997; Luxemburger et al., 1996). It is unclear if a
combination vaccine would meet the needs of both types of regions.

8

4.0 Cambodian Population
Cambodia is a small country in Mekong subregion of Southeast Asia,
adjacent to Thailand, Laos, and Vietnam.
provinces.

The country is comprised of 24

According to the last census taken in 2008, Cambodia had

13,388,910 inhabitants (NIS, 2008). In Cambodia, Dengue fever, tuberculosis,
HIV, intestinal parasitic infections, and malaria are the most endemic diseases.
For malaria, most cases are centralized around Cambodia’s dense forest
regions, along the Thai and Vietnam borders (Cui et al., 2011). The two most
prevalent species of malaria here are P. falciparum and P. vivax, constituting
over 80,000 malaria cases in 2008 (Cui et al., 2011; Dysoley et al., 2008).
4.1 The Forests of Cambodia. The forests of Cambodia, like many areas
in Southeast Asia, constitute a low, seasonally transmission P. vivax infections
(Luxemburger et al., 1997; Dysoley et al., 2008). When non-forest inhabitants go
into the forest to work during the rainy season, from April to December, they may
return to their homes with a P. vivax infection. Medications are readily available
over the counter and are relatively inexpensive; however, due to unsupervised
medication regiments, this process has been leading to drug-resistance. Also, P.
vivax can lie dormant for several months, further complicating the malaria
situation (Adak, Sharma, & Orlov, 1998).
4.2 Pursat Province. Pursat, a province in western Cambodia located
along the Thai border, is a typical example of a malaria endemic province.
Although there are five additional districts in Pursat, Veal Vang, along the Thai
9

border, is covered with mountainous forests (Figure 3). The Kravanh district has
some forest in the west, but is mostly known as the forest fringe. Karkor, Bakan,
and Kandieng are all districts that border Cambodia’s Great Lake, Tonle Sap
Lake. Sempov Meas contains the district capital, also known as Pursat. In
2008, Pursat province had a population of 397,161 (NIS, 2008). Although the
largest district by land mass, Veal Vang contained 3.2% of the province’s
population with only 13,052 people (NIS, 2008). The people of this region are
highly migratory, making it difficult to track malaria infections among them. Also,
due to the dense terrain, inhabitants of the forest region are difficult to reach.

10

Figure 3: Map of Pursat Province in Western Cambodia. The district borders of Pursat province
as of the 2008 census. District names, provided in Khmer have been translated into English.
TheVeal Vang district on the western border of Pursat is along the Thai/Cambodia border, while
the north eastern border is along the Tonle Sap Lake.
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Although Veal Vang is the least populated district in Pursat province,
approximately 51.2% of the population makes their living on work done there;
including market-oriented and subsistence agriculture, mining, and lumber.
205,478 men and women, ranging from age 5 to 97 make their living in the forest
(NIS, 2008). The forest is also the main breeding ground for Aneopholes dirus,
the main malaria vector in the Mekong region (Phimpraphi et al., 2008).

In

general, workers arrive in the forest free of malaria infections, but return home
infected; similar to the pattern of infection in the forest region of Thailand, along
the Myanmar border (Dysoley et al., 2008). Also, although it hasn’t been as well
documented as the Karen communities in Thailand, it is believed that year round
inhabitants of Veal Vang show signs of acquired immunity with age due to a
more constant exposure to malaria.
4.3 Pursat Collaboration. Dr. Rick Fairhurst, M.D., Ph.D. of the NIH/NIAID
is conducting a study in Pursat province to better understand P. vivax infection in
the low endemic regions.

The five year study, beginning in 2008, took place at

the Pursat Provincial Clinic in the capital of Pursat where data was collected from
April to December (the perceived rainy season). Individuals suspected of malaria
infections either came to the clinic or were collected along the Hwy 5, the main
road leading to Veal Vang.

All malaria screenings took place at the Pursat

Provincial Clinic and treatment was provided regardless of enrollment in the
study. Only volunteers that satisfied the inclusion criteria and provided informed
consent were enrolled in the study and asked to donate no more than 24ml of
12

blood. In 2008, enrolled volunteers ranged from 2-75 years of age, with 150
males and 86 females (Table 1).

Through collaboration with the Pursat

Collection Study we hope to further investigate the distribution and immune
response of DBP variants in a seasonally endemic region. The purpose of this
study is to determine which polymorphic allele of the DBL domain is responsible
for the largest burden of disease in the non-forest districts of Pursat, Cambodia,
and to determine if specific polymorphic alleles are responsible for the burden of
disease. We hypothesize that the prominent DBP polymorphisms will vary by
infection; thereby effecting the immune response throughout Pursat province.
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Table 1: Study Population in Pursat, Cambodia.
Study Population in Pursat, Cambodia
Pursat Collection
Study

Pursat Census

Male

Female

Male

Female

13-18 years
19-30 years
31-50 years
51 and older

4 (80)
2 (33.3)
-

1 (100)
1 (20)
4 (66.7)
1 (100)

10944(50.9)
13988(49.6)
10612(46.4)
5602 (40.9)

19-30 years
31-50 years

3 (100)
5 (83.3)

1 (16.7)

2-12 years
13-18 years
19-30 years
31-50 years

7 (77.8)
8 (100)
27 (96.4)
5 (62.5)

2-12 years
13-18 years
19-30 years
31-50 years
51 and older

Infection Rate
(per 1000)
Male

Female

10574(49.1)
14218(50.4)
12268(53.6)
8090 (59.1)

0.00
0.29
0.19
0.00

0.09
0.07
0.33
0.12

6330 (48.7)
5203 (45.8)

6674 (51.3)
6161 (54.2)

0.47
0.96

0.00
0.16

2 (22.2)
1 (3.6)
3 (37.5)

11070 (51)
6904 (50.9)
9058 (50.3)
7461 (45.7)

10650 (49)
6670 (49.1)
8955 (49.7)
8854 (54.3)

0.63
1.16
2.98
0.67

0.19
0.00
0.11
0.34

10 (50)
8 (42.1)
11 (73.3)
2 (33.3)
2 (50)

10 (50)
11 (57.9)
4 (26.7)
4 (66.7)
2 (50)

8464
5349
6134
5510
2467

(51.9)
(51.9)
(49.4)
(47.5)
(40.5)

7838
4958
6286
6081
3627

(48.1)
(48.1)
(50.6)
(52.5)
(59.5)

1.18
1.50
1.79
0.36
0.81

1.28
2.22
0.64
0.66
0.55

2-12 years
13-18 years
19-30 years
31-50 years

1 (50)
2 (100)
13 (81.3)
3 (75)

1 (50)
3 (18.8)
1 (25)

6705
5347
6516
5515

(51)
(50.5)
(49.1)
(46.2)

6434
5247
6765
6410

(49)
(49.5)
(50.9)
(53.8)

0.15
0.37
2.00
0.54

0.16
0.00
0.44
0.16

2-12 years
13-18 years
19-30 years
31-50 years
51 and older

18 (51.4)
2 (25)
11 (61.1)
5 (45.5)
1 (100)

17 (48.6)
6 (75)
7 (38.9)
6 (54.5)
-

1860
1083
1438
1622
569

(51.8)
(53.4)
(54.2)
(53.7)
(54.0)

1729
945
1215
1396
485

(48.2)
(46.6)
(45.8)
(46.3)
(46.0)

9.68
5.54
7.65
3.08
1.76

9.83
6.35
5.76
4.30
0.00

Bakan

Kandieng

Krakor

Kravangh*

Sampov Meas

Veal Vang*

*Forest districts in Pursat involved with malaria transmission. Inhabitants from other districts travel to the
forest districts for work and return to their home districts with malaria. The infection rate is the number of
number of infected patients in the study compared to the districts population and does not reflect incidence
cases in each district.
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Materials and Methods

1.0 Pursat, Cambodia Collection Study, 2008
Biological, medical, and demographic information was obtained through
the Pursat, Cambodia Collection Study, 2008, under the direction of Dr. Rick
Fairhurst, M.D., Ph.D. at NIH/NIAID. In a brief summary, inhabitants living in
Pursat province, in Western Cambodia, were asked to come to the provincial
medical clinic in the town of Pursat if they were feeling any malaria symptoms,
i.e. fever, chills, paroxysm, or malaise.

At the clinic, Cambodian healthcare

providers performed the routine medical examination that included determining
the patient’s malaria status by finger prick. A certified microscopic technician
prepared and analyzed both a thick and thin blood smear, following the universal
protocol outlined by the World Health Organization (WHO, 2010b). Patients with
isolated P. vivax infections were asked to participate in the study and provide
informed consent if they were ≥ 2 years of age and weren’t found to have any
further self-reported illness that the researchers deemed would hinder patient
compliance or confound the data (HIV infection).

Enrolled participants were

asked to donate one to three Vacutainer tubes of blood to be used for further
research, including determining parasitemia, parasite DNA extraction and
sequencing, human blood typing, diagnostic testing, and serum extraction.
A total of 313 human sera and 108 parasite genomic DNA samples from
the 2008 malaria season were provided to Dr. John Adams’s laboratory facilities
15

at the University of South Florida, College of Public Health, Global Health
Department. De-identified medical records for the 179 participants’ visits were
also provided, based on the honest broker agreement between Dr. Rick Fairhurst
and Dr. John Adams (Appendix A).

Participant visits consisted of the acute

(enrollment) visit, the convalescent visit (3-5 weeks after the acute visit), and any
repeat-acute visits (beyond the 5 week convalescent period). Parasite genomic
DNA was only provided from the acute visit.

16

2.0 DNA Sequence Analysis
The 108 genomic DNA samples were sequenced by Dr. John Adams’s lab
using the DNA sequence company GeneWiz (South Palinfield, NJ). Briefly, DBP
region II (DBPII) was isolated from the genomic DNA and amplified via PCR. At
least 400ng of each PCR product along with forward and reverse sequencing
primers was sent to GeneWiz for nucleic acid sequences. GeneWiz returned the
nucleic acid sequences available for 81 of the 108 samples.
Using conserved epitopes found in DBPII-Sal 1, the universal control for
DBPII sequences, the nucleic acid sequences were translated to amino acid
sequences and were aligned to five the DBPII test variants (Sal 1, 7.18, O, P,
and AH).

A clustalW alignment with the PAM protein weight matrix was

performed in MEGA 5.05 (Tempe, AZ). The PAM protein weight matrix weighs
sequences based on how different the amino acid substitutions are from each
other, i.e. if both amino acids are hydrophobic or polar (Baxevanis & Ouellette,
1998). Since DBPII is comprised largely of conserved sites, with few known
polymorphisms, only amino acid substitutions that result in a true variation to
DBP were desired.
A phylogenetic tree was constructed in MEGA 5.05 based on the results
from the clustalW alignment.

The tree was constructed using the neighbor-

joining statistical method, the bootstrap phylogeny test with 1000 replicates, the
Dayhoff model for amino acid substitution, and complete deletion of missing data
and gaps. The phylogenetic tree also produced a table of evolutionary distances,
17

which expresses the sequence distance on the tree as a scalar value (Baxevanis
& Ouellette, 1998).
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3.0 ELISA
A total of 313 serum samples were provided to Dr. Adam’s lab from the
Pursat, Cambodia Collection Study; including 179 acute sera, 79 convalescent
sera, and 55 repeat acute sera. ELISAs were used to determine each samples
antibody binding affinity to multiple DBPII variants.

Five recombinant DBPII

(rDBPII) variants, produced in Dr. Adams’s lab and used in previous studies
pertaining to Papa New Guinea, were selected for serological testing because
they were representative of variant DBP strains found in various geographic
regions around the world, including Southeast Asia, South America, Western
Africa, and the Pacific Islands (Cole-Tobian et al., 2009; unpublished data). DNA
from variant strains was used to produce the pure rDBPII to act as the antigen
used in the stationary phase for ELISAs.
3.1 General ELISA Protocol. A direct ELISA method was used to
investigate the antibody binding affinity for all Pursat, Cambodia sera. Direct
ELISAs include four main components; the antigen, the primary, antigen-specific
antibody, the secondary antibody specific for the type of primary antibody, and
the antibody substrate (Crowther, 2000). During opimization, Immulon 96-well
plates (Thermo-Scientific) were coated with 50µl of a 2µg/ml concentration of
rDBPII-Sal 1 and incubated overnight at 4oC. The plate was washed with a wash
buffer (PBS/0.05% Tween 20) three times. The plates were blocked with 100µl
of blocking buffer (5% nonfat milk/PBS/0.05% Tween 20) at room temperature on
a plate shaker for 2 hours. The plates were washed with wash buffer three times
19

and 50µl of the primary antibodies was added to the wells; each was diluted
differently based on the experiment. The primary antibody incubated at room
temperature on a plate shaker for 2 hours. The plates were washed with the
wash buffer three times and 50µl of the secondary antibody was added to each
well at a 0.5µg/ml concentration. The secondary antibody was a goat anti-human
phosphotase antibody that binds to human made antibodies. The secondary
antibody incubated at room temperature for 1.5 hours on a plate shaker. The
plates were washed with the wash buffer three times and 50µl of substrate
solution was added to each well.

The substrate used was a phosphotase

substrate system that binds specifically to the phosphotase of the secondary
antibody.

The substrate changes color relative to the amount of secondary

antibody bound to the plate. Since the substrate is photosensitive, plates were
wrapped in aluminum foil and placed in a dark cabinet for 20 minutes. The
degree of color change was measured using a spectrophotometer and optical
density (OD) values were recorded.
3.2 ELISA Control Selection. Prior to testing experimental sera a positive
human serum control was needed as a standard curve, used for normalizing the
antibody response to multiple samples, and a negative human serum control was
needed as a quality control, to prove any binding observed during the ELISAs
wasn’t due to nonspecific binding of the secondary antibody to the antigen and to
determine the cut-off value for the experimental sera. High titer human sera from
a previous study in Papua New Guinea were tested individually in ELISAs and
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pooled as the standard curve (King et al., 2008). The positive pooled serum was
titrated using doubling dilutions and half-log dilutions, starting at 1:10, to
determine which dilution pattern produced the most complete dose-response
curve. The standard curve, using half-log dilutions, was performed on each plate
coated with rDBPII antigen.

Twelve North American, malaria naïve negative

control serum were tested at a 1:100 dilution to determine reactivity and those
with an OD value below 0.055 were pooled for the negative control. The 95%
confidence interval of the t-distribution of the individual negative sera OD values
were used to determine the cut-off value for the experimental sera (Equation 1)
(Dixon & Massey, 1983; Frey, Di Canzio, & Zurakowski, 1998).
Equation 1: Cut-off Determination
    



 



1
  1  


where n=number of negative sera in the pooled control
degrees of freedom=11

To determine the spectrum of reactivity for the experimental Cambodian
sera, the first 21 convalescent sera were screened, through ELISA, against the
standard curve. It was believed that the convalescent sera would have a higher
antibody titer than the acute sera, providing an expected maximum range for
antibody response.

From this screen, the highest, lowest, and middle

responders were selected to be titrated to visualize the reactivity spectrum.
Based on these curves the 1:200 dilution was selected because it best described
the antibody response for all three sera.
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3.3 Experimental ELISAs. To test the experimental sera, Immulon 96-well
plates were coated with 100µl of a 2µg/ml concentration of each rDBPII antigen
(Sal 1, 7.18, P, O, and AH) and incubated overnight at 4oC. This was to ensure
maximum coverage of the wells. After washing and blocking the plates, they
were washed as previously stated and 100µl of the primary antibodies of varying
types were added to the wells (Figure 4).

22

A
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D
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1
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SC-1000 SC-1000 SC-1000
SC-3162 SC-3162 SC-3162
SC-10k SC-10k SC-10k
SC-31622 SC-31622 SC-61322
neg-1000 neg-1000 neg 1000
Sample 1 Sample 2 Protein
Sample 1 Sample 2 Sample 1
Sample 1 Sample 2 Sample 2

4
Sample 3
Sample 3
Sample 3
Sample 3
Sample 4
Sample 4
Sample 4
Sample 4

5
6
7
8
9
10
11
12
Sample 5 Sample 7 Sample 9 Sample 11 Sample 13 Sample 15 Sample 17 Sample 19
Sample 5 Sample 7 Sample 9 Sample 11 Sample 13 Sample 15 Sample 17 Sample 19
Sample 5 Sample 7 Sample 9 Sample 11 Sample 13 Sample 15 Sample 17 Sample 19
Sample 5 Sample 7 Sample 9 Sample 11 Sample 13 Sample 15 Sample 17 Sample 19
Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20
Sample 6 Sample 8 Sampe 10 Sample 12 Sample 14 Sample 16 Sample 18 Sample 20

Figure 4: ELISA Plate Map. The standard curve (green) is the pooled positive serum was diluted
at 1:1000, 1:3162, 1:10,000, and 1:31622. The pooled negative control serum (blue) was diluted
at 1:1000. The protein control (blue) was where antigen was coated on the plate, but was not
probed with a primary antibody. The PBS coated wells (red) were probed with the same
experimental sera to determine the amount of non-specific binding occurs due to the
experimental antibody. All Cambodian experimental sera (denoted as “sample”) were diluted at a
1:200 dilution.
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The experimental sera, diluted at 1:200 were added to the plate in triplicate. The
standard curve was diluted using half-log dilutions, starting with a 1:1000 dilution,
and added to the wells in duplicate, representing the log phase of the standard
curve. The pooled negative control serum was added in duplicate to the antigen
coated wells to show that antibodies not produced to DBPII will not bind to the
rDBPII. All types of primary antibodies were also added to the PBS wells, which
were coated with PBS and not the test antigen. These wells act as a serum
control to determine the amount of non-specific binding that occurs due to the
antibody. There was one well without any primary antibody added to act as the
antigen control, used to determine if there was any non-specific binding was due
to the rDBPII. The primary antibody incubated at room temperature on a plate
shaker for 2 hours. The plates were washed as previously stated and the goat
anti-human phosphotase secondary antibody was added to each well at a
0.5µg/ml concentration. The secondary antibody incubated at room temperature
for 1.5 hours on a plate shaker. The plates were washed as before and the
phosphotase substrate solution was added to each well. Plates were wrapped in
aluminum foil and placed in a dark cabinet for 20 minutes. The degree of color
change was measured using a spectrophotometer and OD values were
recorded.
3.4 ELISA Calculations. Each primary antibody was tested against each
rDBPII antigen, in triplicate, and a PBS coated well. The OD value from each
serum control well was subtracted from its corresponding experimental well,
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removing the effect of any background, non-specific binding due to the serum.
All experimental OD values below the cut-off of 0.055 were considered nonresponders to the rDBPII antigen. The triplicate values, minus the background,
were averaged and normalized compare to the standard curve value with an OD
value closest to 1.0 (Equation 2).
Equation 2: ELISA normalization
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Sera with ELISA units within the upper ELISA unit quartile for each type of
experimental sera (acute, convalescent, and acute-repeat), were considered high
responders to the specific rDBPII antigen. Those sera above the cut-off OD
value, but within the lower ELISA unit quartile for each experimental sera type
was classified as a low responder to the specific rDBPII antigen. Those sera
between the upper and lower ELISA unit quartiles were considered mid
responders to the specific rDBPII antigen.
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4.0 Analysis of Medical and Laboratory Data
Medical data from the Pursat, Cambodia collection Study, 2008 was
reviewed for duplicate data.

“Episode” and “follow_up” variables account for

convalescent and repeat-acute sera values (Table 2). Medical variables (“fever”,
“headache”, “body ache”, “malaise”, “vomiting”, “paroxysm”, “shivering”, “chills”,
and “sweating” ) were converted from character variables to binary coding (0=no,
1=yes).

Demographic variables (“gender”, “location”, and “residence”) were

converted from character variables to numeric variables.

When the numeric

variable “temperature” was cross-referenced with the variable “fever” a large
discrepancy was found; patients who answered “yes” to the question “Do you
have a fever?” did not necessarily present a temperature during the medical
examination. A new variable was created characterize a fever based on the
numeric “temperature” variable and not based on the self-reported fever variable.
This inaccuracy led to a fear that all self-reported variables are untrustworthy and
not validated. There may have been an issue with the way the questions were
worded. Because of this, they were excluded from analysis. Continuous ELISA
units and categorical ELISA values (high, mid, or low responder) for each sample
were added to the Pursat, Cambodia Collection study data set. Also, Pursat
census data (gender, age, and district) from 2008 was added to a copy of the
Pursat, Cambodia Collection study data set.
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Table 2: Data Dictionary for Pursat, Cambodia Collection Study, 2008.

The data dictionary was used to convert the character variables into numeric variables. Variables
used to make the data dictionary come from the original Pursat, Cambodia Collection Study.
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5.0 Research Question 1: Which Variant of the DBL Domain is Responsible
for the Largest Burden of Disease in the Pursat Study?
The surrogate outcome variable used to measure the burden of disease in
Pursat, Cambodia was antibody binding affinity to the variant rDBPII antigens. It
has been shown in previous research that variants of DBPII present differing
binding affinities during serological tests (Ceravolo et al., 2009; Chootong et al.,
2010; King et al., 2008). The main exposure variable to represent the variation of
the DBL domain was measured by the evolutionary distance the amino acid
sequence was from the DBPII control sequence, DBPII-Sal 1. Since it wasn’t
possible do determine if participants were infected simultaneously with multiple
variants of DBPII and because parasite DNA wasn’t available for all sera, the
ELISAs could also be used to determine if the antibodies produced were specific
to one strain or multiple strains.
5.1 Logistic Regression Procedures. Ordinal logistic regression was the
preferred method to determine the relationship between the evolutionary
distances each from DBPII-Sal 1 and antibody binding affinity because it could
be used to determine how the binding affinity affected the odds ratio. This would
provide information about whether the dominant antibodies were binding to a
conserved epitope of DBPII or a polymorphic epitope. Since extreme antibody
affinities provide better information about the infecting parasite, mid responders
were chosen as the control group and the non, low, and high responders were
coded as the experimental groups, coded 1-3 respectfully.
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5.1.1 Ordinal logistic regression.

The ordinal regression was used to

determine the effect the DBPII variant had on the binding affinity of anti-sera to
rDBPII variants.

The outcome variable was categorical and compared the

general population to the extremes.

The reference group was the mid

responders because people infected with P. vivax should present an average
antibody response to a variant.

The extreme binding affinities were of

importance because these participants may be exhibiting a more strain-specific
immune response related to the DBPII variant of their infection.
The assumption of parallel regression was test prior to performing the
ordinal regression, also known as the proportional odds assumption, with the test
score chi-square. According to the proportional odds assumption, the slopes of
the individual outcome levels must be parallel, or proportional, to each other.
This means that the main exposure variable has to have a similar effect on each
outcome variable level (Brant, 1990; O'Connell, 2000). Since they were analyzed
separately, the test score chi-square had to be done for each rDBPII antigen.
This assumption was satisfied for rDBPII-AH only.

Therefore, the ordinal

regression could only be performed on the ELISA results for rDBPII-AH.
Since the antibody binding affinities are expressed in an ordinal
relationship, the ordinal regression was the first choice to provide the odds ratios
for the relationship between the evolutionary distance from DBPII-Sal 1 and the
binding affinity to each antigen.

The ordinal logistic regression (Equation 3)
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determines the effect the exposure, evolutionary distance, has on the increased
ordinal levels of the outcome, antibody binding affinity (O'Connell, 2000).
Equation 3: Ordinal Logistic Regression
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The advantage of using this method is that the cumulative odds ratio can be
generated for the data, meaning that the odds of one binding affinity level or a
combination of multiple binding affinity levels are all considered at the same time.
The cumulative odds gives more information about the effect evolutionary
distance has on the increasing binding affinity levels as opposed to the looking at
the regression of these levels separately. This method could only be used on the
antibody response to rDBPII-AH.
5.1.2 Nominal logistic regression. The nominal regression was used for
the remaining rDBPII antigens. This generalized logit model does account for a
multilevel antibody response and does not have to satisfy the proportional odds
assumption; however it is unable to produce a cumulative odds ratio because the
levels are not taken in order. As opposed to considering binding affinity as it
increases, the nominal regression considers each binding affinity level in no
particular order (Equation 4) (Hedeker, 2003).
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Equation 4: Nominal Logistic Regression: Generalized Logit Model
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Where 3> = an experimental antibody binding level

3# = the control antibody binding level (mid-responders)

With this method it is very important to pre-determine the control values (midresponders) and to pay close attention to the order of the additional outcomes
(non-responder, low responder, and high responder). For both the ordinal and
nominal regressions there was not enough power to test each level due to low
sample size, especially the non-responder level, to support the methods;
therefore the traditional logistic regression was considered.
5.1.3 Logistic regression. The multiple antibody levels were removed from
simultaneous consideration and the logistic regression was used to determine
the separate relationships between on specific level compared to all other levels.
With this method one level, for example the low responder level, was compared
to the combination of all other levels (Equation 5); meaning the odds of being a
low responder compared to the odds of responding any other way.
Equation 5: Logistic Regression
-
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However, this didn’t increase the sample size enough to increase the power for
the analysis. At this point it was decided that it wasn’t possible to obtain odds
ratios to describe the relationship between evolutionary distance and antibody
binding affinity.
5.2 Generalized Linear Model.
5.2.1 Fit the generalized linear model. Since categorizing the antibody
binding affinity for a logistic regression diminished the power for the model, the
antibody binding affinity and evolutionary distance were taken as continuous
variables and used in a generalized linear model (GLM). The GLM allows the
antibody binding affinity to fit a specified distribution and appropriate link function.
The link function is used to specify the relationship between the evolutionary
distance and the binding affinity because the relationship isn’t naturally linear
(McCullagh & Nelder, 1989). Since the data follow a more logistic pattern than a
linear pattern the log link function was used.

The crude model for the

relationship between the evolutionary distance from DBPII-Sal 1 and the binding
affinity for each of the rDBPII antigens was used to determine a separate
distribution which was appropriate for the individual rDBPII antigens.

The

Pearson chi-square (Equation 6) was used to measure the goodness-fit for each
model (McCullagh & Nelder, 1989).
Equation 6 Pearson Chi-Squared Goodness of Fit
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Where y= is the binding affinity for a specific rDBPII

32

If the p-value for the Pearson chi-square was less than or equal to 0.05, then the
distribution was accepted. As a result, DBPII-Sal 1, 7.18, O, and AH used the
Inverse Guassian distribution and DBPII-P used the gamma distribution. The log
link function was appropriate to use for both distributions (McCullagh & Nelder,
1989; Nelder & Wedderburn, 1972).
5.2.2 Confounding exploration. Once the valid models were selected, the
crude and adjusted values were compared. Possible confounding variables were
explored only if they were biologically applicable to the investigation.
Demographic variables (gender, age, and resident district) were examined first.
Age was considered as a continuous variable and as a categorical variable.
Initially the five age groups were 2-12 years, 13-18 years, 19-30 years, 31-50
years, and 51 years or older.

These groups were chosen based on

internationally understood age ranges and an attempt to control the frequency in
each group, except for the oldest group. Since there wasn’t enough power for
the numerous groupings for the GLM, the age groups were collapsed into two
groups, those 18 years or younger and those over the age of 18. There wasn’t
enough power for these groups either.

Resident district was originally

categorized as the six districts (Sampov Meas, Bakan, Krakor, Kandieng,
Kravagh, and Veal Vang). There wasn’t enough power for this analysis, so the
districts were collapsed into two groups, the forest districts (Kravagh and Veal
Vang) and the non-forest districts (Sampov Meas, Bakan, Krakor, and Kandieng).
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Medical variables (temperature, blood pressure, heart rate, respiratory
rate, hemoglobin level, parasitemia, blood type and Rh type) were also explored
for counfounding. Numeric temperatures were categorized as being feverish,
37oC and above, and normal, below 37oC. The heart rate, respiratory rate, and
blood pressure were for all participants were seen to be within normal
parameters; therefore, they were not explored as confounding variables.
hemoglobin level variable was explored as a categorical variable.

The
Those

participants with a hemoglobin level less than 11g/dL were considered anemic
and those with a hemoglobin level less than 7g/dL were considered severely
anemic.

Anemia and severe anemia were categorized as two separate

variables. Parasetemia was explored as a continuous variable. Blood type and
Rh type were explored as categorical variables. Also, month of clinic visit and
participant collection location (clinic or mountain) were also explored for
confounding.
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6.0 Research Question 2: Are specific polymorphic alleles responsible for
the burden of disease?
To obtain a better understanding of the distribution of P. vivax variants, it
is important to not only know how the variants differ, but also to know how those
differences affect the burden of disease.

The correlation between specific

polymorphisms and antibody binding affinity, used as a surrogate for burden of
disease, was explored. This correlation was to identify antibody responses that
were strain-specific or strain-transcending and to determine if any specific
polymorphism was related to the antibody response.
6.1 Correlation Analysis for Antibody Response.

The first correlation

analysis was to determine if antibody response levels to the various rDBPII
antigens were related. The low and high antibody affinity levels used for the
ordinal regression were used for the separate correlations. The sample size for
the non-responders was too low and was not considered in this analysis. Again,
the mid-responders constituted the general population.

The dataset was

condensed to only include responses for high binding affinity to any rDBPII
antigen tested. Since the antibody binding affinities failed the Anderson-Darling
test for normality, the Spearman rank correlation (Equation 7) was used to
determine the correlation because it is a non-parametric test.
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Equation 7: Spearman Rank Correlation
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Where d=rank difference between antibody binding affinity measurements
n=the number of antibody binding affinity measurements

This analysis helped to determine if the antibody response was high to one DBPII
variant, would it be expected to be high to another DBPII variant.

The same

process was done for low binding affinity.
6.2 Correlation Analysis for a Specific Amino Acid Polymorphism. Further
analysis was performed to determine if the specificity of the antibody response
could be attributed to a specific polymorphic amino acid. Using the DBPII-Sal 1
sequence as the control sequence, the polymorphisms in the Cambodian
genomic DNA sequences were given binary coding (0=same amino acid as
DBPII-Sal 1, 1=different amino acid than DBPII-Sal 1).

The point-biserial

(Equation 8) correlation was used to determine if antibody binding affinity was
correlated to specific amino acid substitutions.
Equation 8: Point-Biserial Correlation
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Where Y= the score mean for each rDBPII antigen
s = standard deviation of the sample
n=the sample size for each rDBPII antigen

This analysis explored the correlation between a dichotomous variable,
specific alleles, and a continuous variable, antibody binding affinity. To adjust for
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possible confounding variables, a partial point-biserial correlation was performed.
Demographic variables (gender, age, and resident district) were tested first. Age
was explored as a categorical variable in two groups, 18 years and below and
above 18 years. Resident district was also explored as a categorical variable in
two groups, forest districts and non-forest districts. The same medical variables
tested in the GLM method were also tested for confounding.
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Results

1.0 DNA Sequencing and Evolutionary Distances
Parasite genomic DNA was aligned and sequenced using MEGA 5.05. A
phylogenetic tree was constructed the using neighbor-joining statistical method.
The bootstrap phylogeny test with 1000 replications and the Dayhoff method was
used for amino acid substitution. Of the 89 sequences, 29 were in the same
clade as DBPII-Sal 1(Figure 5). DBPII-O also had a high number of similarities
with 15 Cambodian samples in its clade. DBPII-AH had the lowest number of
similarities, with only one Cambodian sample in the same clade.
Evolutionary distance was used to measure the degree of polymorphic
changes among the Cambodian parasite DNA. Because there were very few
polymorphic variations within the 222 amino acid alignment, the evolutionary
distances from DBPII-Sal 1 were very small (Table 4).

According to the

evolutionary distance, 24, approximately 30%, acute Cambodian samples were
the same as the DBPII-Sal 1, with an evolutionary distance of 0, while only 1
Cambodian sample had an evolutionary distance of 0.31, the farthest distance
from DBPII-Sal 1.
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Figure 5: Cambodian Acute Parasite Phylogenetic Tree. Parasite genomic DNA from 81 acute
Cambodian samples were amplified through PCR and sequenced by GeneWiz. Protein
sequences were aligned using a ClustalW alignment with a PAM protein matrix. A phylogentic
tree comparing the Cambodian samples to the five test variants constructed using the neighborjoining statistical method, bootstrap phylogeny test, with the Dayhoff model of amino acid
substitution. The majority of Cambodian parasite DNA is similar to the control DNA, DBPII-Sal 1.
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Table 3: The Frequency of Evolutionary Distances from DBPII-Sal 1.
Evolutionary
Distance
from
DBPII-Sal 1
0
0.018
0.0364
0.0551
0.0741
0.0935
0.1133
0.1135
0.1335
0.1542
0.3118

Frequency
24
5
4
13
6
2
8
1
13
2
1

Percentage
30.38
6.33
5.06
16.46
7.59
2.53
10.13
1.27
16.46
2.53
1.27

The evolutionary distances from DBPII-Sal 1 were calculated based on the phylogenetic tree.
Because the same were so similar to each other, all samples fit within 11 distances. The
frequency was based on the number Cambodian samples with that distance and the percentage
is based on the 81 samples.
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2.0 ELISA Analysis
2.1 ELISA Optimization. Prior to the serological analysis of the human
sera from 179 Cambodian study participants a pooled positive standard human
sera was selected and a pooled human sera naïve to malaria was screened to
optimize the protocol. Pooled human serum from Papua New Guinea with high
antibody titers for DBPII was used as the positive standard curve. The standard
curve was titrated using both doubling dilutions and half-log dilutions (Figure 6).
The half-log dilutions provided all the properties of the reaction curve; therefore,
was the dilution scheme adopted for the experimental ELISAs. The standard
curve was performed on each rDBPII variant to provide a reaction pattern for
each antigen (Figure 7).

The pooled positive serum was found to react similarly

to each recombinant protein.
The DBPII-Sal 1 standard curve was compared to three randomly selected
experimental Cambodian sera (Figure 8). The reactivity of the pooled positive
serum was aligned with the reactivity of the selected Cambodian sera. Based on
the aligned values, a 1:200 dilution was selected to test all experimental sera.
Individual North American malaria naïve sera were screened against
DBPII-Sal 1 and those sera with an OD value below 0.055 were pooled for the
negative control (Figure 9). North American samples 401, 402, 403, 405, 410,
411, 412, 413, 414, 416, and 417 were chosen for the pooled negative control
sera. The negative control serum was placed on each experimental plate at a
1:1000 dilution.
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a.)

b.)

Figure 6: Standard Curve Dilutions. Pooled positive serum from PNG were titrated using two
dilution patterns to produce the standard curve. Error bars represent the one standard deviation
away from the mean OD value of triplicate wells at each dilution.
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Figure 7: Standard Curve for rDBPII Antigens. The PNG pooled positive serum was diluted, halflog dilutions, against the five test rDBPII antigens. The log phase of each dilution curve was fit to
a line to locate a dilution factor that can be used to normalize all experimental values.
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Figure 8: Selection of Experimental and Standard Dilutions. a.) The standard curve was titrated
using half-log dilutions. Several Cambodian convalescent field sera were screened against the
pooled positive serum to compare reactivity. b.) The highest, lowest, and a middle responder
were chosen to be completely titrated. The standard curve was found to have a higher binding
affinity than the experimental sera. The lines represent the corollary antibody dilutions
considered for both the standard curve and the experimental sera.
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Figure 9: Pooled Negative Control Sera Selection. Negative control sera were screened from
multiple North American malaria naïve individuals to decide which to pool for the negative control
and use to calculate the cut-off point.
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2.2 Experimental ELISAs for All Recombinant Proteins.

ELISAs were

performed for each rDBPII antigen on each type of sera (acute, convalescent,
and repeat-acute). High responders for the experimental sera were identified as
those sera in the upper quartile range of each type (Figures 10-12). Based on
the high responders, strain-specific and strain-transcending sera were identified.
Strain-specific sera were identified as those sera that were highly reactive to no
more than two rDBPII antigens.

Strain-transcending sera were identified as

those that reacted highly to four or more of the rDBPII antigens.

The

convalescent and repeat-acute sera produced more strain-specific sera than the
acute sera; however, the reactivity of these sera was far lower than that of the
acute sera. This reactivity pattern was different than expected. Also, due to
sample restraint, there were few opportunities for temporal comparisons of an
individual’s sera. For this reason, the convalescent sera and the repeat-acute
sera were not considered for further analysis.
Strain-specificity suggests the serum bind to an epitope not found in the
other DBPII antigens. This allows sera to be mapped to certain polymorphic
alleles. It is important to note that DBPII-AH produced the most strain-specific
reactions to the acute Cambodian sera, suggesting those sera are reacting to an
epitope not found in the other DBPII antigens. Since the only difference between
DBPII-7.18 and DBPII-AH is the K371E polymorphism, it is hypothesized that the
sera are reacting to an epitope including this polymorphism.
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Strain-transcending sera are hypothesized to bind to an epitope found in
multiple DBPII antigens, thought to be conserved epitopes. It is important to note
that only two acute sera are highly reactive to all five rDBPII antigens; therefore
it’s hypothesized that these sera bind to a conserved epitope found on all DBPII
variants.

None of the convalescent sera were found to have a high binding

response to four or more DBPII variants, meaning that the convalescent sera
were found to be more strain specific. Only one or the repeat-acute responders
was found to have a strain-transcending antibody response and that individual
didn’t exhibit a high antibody binding affinity to the variants on the acute visit.
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Figure 10: High Acute Responder Comparison. High responder sera during the acute visit was
identified as those sera with an antibody affinity within the upper quartile. Approximately half of
high acute responders demonstrate a strain-specific immune response to only one DBPII variant,
with DBPII-AH exhibiting the most strain-specificity. This sera demonstrating a high response to
DBPII_AH are not as likely to exhibit a high immune response to DBPII-7.18.
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Figure 11: High Convalescent Responder Comparison. High responder sera was identified as
those sera with an antibody affinity within the upper quartile of the convalescent sera. The
convalescent sera exhibits less of a strain-transcending immune response, which only four sera
binding to three variants.
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Figure 12: High Acute-Repeat Responder Comparison. High responder sera was identified as
those sera with an antibody affinity within the upper quartile of each the repeat-acute sera. The
repeat acute sera exhibit less strain-transcending immune responses, with only three sera
binding to three or more variants.
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3.0 Logistic Regression Analysis
3.1 Ordinal and Nominal Regression Analysis. The antibody binding
affinity was categorized into four levels, as described in the methods. Because
the antibody responses to DBPII-AH were the only responses that satisfied the
proportional odds assumption, the ordinal logistic regression was only used on
that variant. The nominal logistic regression, with the mid responders as the
reference group, would provide odds ratios to compare between each group as
opposed to the cumulative odds ratios the ordinal logistic regression would
provide.
According to the results of both the ordinal and nominal regressions, there
is not enough power to determine an appropriate odds ratio (Table 4). Many of
the odds ratios provided were too large to calculate (>999.99) or too small to
calculate (<0.001). Moreover, the confidence intervals, although significant, were
infinitely large and unable to be calculated. The lack of power was either due to
a low sample size of the reference group for each DBPII variant or due to a low
sample size in each categorical level. It wasn’t clear from this analysis which
situation would have caused these odds ratios.
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Table 4: Results of the Ordinal and Nominal Regression

Only DBPI-AH (red) satisfied the proportional odds assumption, so it was the only antigen to
undergo ordinal regression. The remaining antigens were able to undergo nominal logistic
regression, which doesn’t have to satisfy the proportional odds assumption. The small sample
size for each antibody affinity level didn’t provide the amount of power needed for this type of
analysis.
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3.2 Simple Logistic Regression Analysis. A simple logistic regression was
performed to determine if there was an association between evolutionary
distance and each separate categorical level of the antibody response. Antibody
response at each level was given a binary category, with the reference group
containing all antibody response levels except the level being tested. This would
increase the sample size of the reference group and thereby increasing the
power of the analysis. The odds ratios produced wouldn’t be cumulative, but it
would still be possible to compare odds ratios between groups.
Although the simple odds ratio does increase the sample size of the
reference group, this was not enough to increase the power for this analysis
(Table 5). That means the sample size in each level was too low to produce
adequate odds ratios. Since I feel it is very important to know the differences
between low and high responders, I didn’t feel it was appropriate to combine
antibody binding levels to increase the sample size of the experimental groups.
Also, since the sample size within antibody levels was too small, there was no
need to adjust for confounding. The odds ratios couldn’t be interpreted in their
crude or adjusted forms.
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Table 5: Results of the Logistic Regression

A logistic regression, using binary coding for each antibody response level, was used to show the
relationship between the evolutionary distance from Sal 1 and the antibody binding affinity. Each
response variable level is coded as 1=desired level and 0=all other levels. The crude regression
was revealed that the sample size was still too small and there wasn’t enough power to perform
this analysis.
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4.0 GLM Analysis
Since the sample size within each antibody binding level was too small,
the antibody binding affinity was taken as a continuous variable to increase the
power of the analysis. A generalized linear model (GLM) was used to explore
the relationship between the continuous evolutionary distance from DBPII-Sal 1
and the continuous antibody binding affinity. The GLM used a log link function,
to explore the data as a log function along an Inverse Gaussian distribution. This
means the parameters determined by the equation are based on a log function.
Using the GLM parameters produced the percent change for each DBPII was
determined.
The crude GLM parameters, those showing the relationship between the
evolutionary distance from DBPII-Sal 1 and the antibody binding affinity to the
different variants, were much higher than those adjusted for parasitemia (Table
5). The crude GLM parameter for DBPII-Sal 1 was 8.54 and dropped to -0.0005
(-0.0008 - -0.0002) when adjusted for parasitemia. The adjusted percent change
was -0.05. This means as the evolutionary distance from Sal 1 increase the
antibody binding response to DBPII-Sal 1 undergoes a slight percent drop, when
controlled for increasing parasitemia. In other words, sera with antibodies to a
variant similar to DBPII-Sal 1 will bind more strongly to DBPII-Sal 1. The other
parameters

weren’t

significant when adjusted for parasitemia.

Other

demographic confounding variables were explored, but none of them changed
the crude GLM parameter.
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Table 6: Results of the GLM

Using both the evolutionary distance and the antibody titer as continuous variables, the
generalized linear model could be used to describe their relationship. The crude parameter
coefficient for the evolutionary distance is compared to the adjusted coefficient, adjusted for
parasitemia. DBPII-Sal 1 became statistically relevant once adjusted for parasitemia.
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5.0 Serologic Response Correlation.
The first step in exploring whether a specific polymorphic site is
responsible for the observed antibody responses is to determine if the antibody
responses for the different variants are related to each other. The Spearmen
Rank correlation was used to test the correlation of the antibody response levels
between variants. Among high responders, there is a correlation in antibody
response between variants DBPII-Sal 1, 7.18, O, and P. This means that sera
responding highly to DBPII-Sal 1 are also likely to respond highly to DBPII-7.18,
O, and P. There is a strong correlation between being a high antibody responder
to DBPII-P and a high responder to DBPII-7.18 or O (r=0.88). The correlations
between DBPII-Sal 1 and the 7.18, O, and P are not as strong. High response to
DBPII-AH is not correlated to any other tested variant. This shows that DBPII-AH
produced a more strain-specific immune response compared to the tested
variants.

This pattern was not obtained for the correlation between low

responders to the variants (Table 6). There is a strong correlation between being
a low responder to one variant and a low responder to other variants.
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Table 7: Correlation of High DBPII Responders

A Spearman rank correlation was used to show the relationship between high responders to
multiple DBPII variants. The correlation coefficient (r) and the p-value suggest that only sera that
bind to DBPII-AH tend to be more strain specific.
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Table 8: Correlation of Low DBPII Responders

A Spearman rank correlation was used to show the relationship between low responders to
multiple DBPII variants. The correlation coefficient (r) and the p-value suggest the experimental
sera respond equally low to all the test rDBPII antigens.
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6.0 Antibody Binding Affinity Correlated to Specific Amino Acids
The polymorphic amino acid sites chosen have been shown to inhibit the
parasite binding to the erythrocyte. In addition, the amino acid at site 371 is the
only amino acid change difference between DBPII-AH and 7.18, a glutamic acid
substituted for the lysine, and is thought to be involved with the immune
response difference between the two variants. The scope of the polymorphisms
was compared at these sites (Figure 13). The prominent amino acid sequences
were listed and color-coded to show their position on the DBPII homology
structure.

All the selected polymorphic alleles were shown on the surface,

except the 437 site, which is partially hidden.
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Figure 13: Allele Variations and Locations. The five test DBPII variant sequences were aligned
with the prominent genomic parasite DNA of the acute Cambodian visits, each numbered
sequence appeared at least once in Cambodia. Important amino acid substitutions, possibly
used to evade the immune system, are highlighted in the table and the molecular homology
model of DBPII. The K371E substitution (green) is the only amino acid difference between
DBPII-7.18 and DBPII-AH and is responsible for the different binding affinity patterns between the
variants. The amino acids at 384-386 (blue) are considered to be the most polymorphic in DBPII
and are thought to be located near the erythrocyte binding site. The amino acids at 417, 424, and
437 (red) are thought to be important in erythrocyte binding inhibition. The yellow highlighted
region is also a common polymorphism in region II.
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The point-biserial correlation was used to determine the correlation
between specific amino acid sites and antibody binding affinity to the test
variants. The amino acid sequence for DBPII-Sal 1 was used as the control
sequence.

Each polymorphic site was correlated to the continuous antibody

binding affinity to each of the test variants. The crude point-biserial coefficient
was compared to the adjusted coefficient, adjusted for location of the patient’s
collection (the road or the clinic) (Tables 7 and 8).
Despite the amino acid difference between DBPII-Sal 1 and AH, there was
no correlation between the 371 amino acid and antibody binding affinity. There
was also no correlation between the 371 amino acid site and DBPII-7.18, which
has the same glutamic acid as Sal 1. The correlation does reaffirm the 384-386
amino acid sites are loosely correlated to antibody binding affinity. This loose
correlation was also seen at site 390 and 437. It is unclear which specific amino
acid is responsible for the immune response.
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Table 9: Results of Amino Acid Correlation

Amino acids that have been shown to be important for antibody binding and inhibitions of
erythrocyte binding were examined to identify a correlation between the amino acid substitution
and the antibody binding affinity to the variant. The substitution of selected amino acids, based
on the control sequence of DBPII-Sal 1, were coded using binary code (0=the same amino acid
as DBPII-Sal 1, 1= a different amino acid than DBPII-Sal 1). A point biserial correlation was used
to assess the relationship between the binary amino acid and the continuous antibody binding
affinity. The point biserial correlation coefficient (ρpb) was used to determine the direction and
strength of the correlation. A partial correlation was used to adjust for location.
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Table 10: Amino Acid Correlation Adjusted for Location

Amino acids that have been shown to be important for antibody binding and inhibitions of
erythrocyte binding were examined to identify a correlation between the amino acid substitution
and the antibody binding affinity to the variant. The substitution of selected amino acids, based
on the control sequence of DBPII-Sal 1, were coded using binary code (0=the same amino acid
as DBPII-Sal 1, 1= a different amino acid than DBPII-Sal 1). A point biserial correlation was used
to assess the relationship between the binary amino acid and the continuous antibody binding
affinity. The point biserial correlation coefficient (ρpb) was used to determine the direction and
strength of the correlation. A partial correlation was used to adjust for location.
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Discussion
1.0 Antibody Response Over Time.
The Purst, Cambodia Collection Study was a cross-sectional study
designed collect active and passive surveillance data about P. vivax infections
from inhabitants of Pursat Province. During the study researchers from Dr. Rick
Fairhurst’s laboratory collected medical and demographic information about
individuals infected with P. vivax, as well as blood samples to test human and
parasite characteristics. The goal of this descriptive study was to characterize
the serologic response to P. vivax in a seasonally endemic region using human
sera and parasite genomic.
Dr. Adams’s laboratory was provided with acute, convalescent, and
repeat-acute sera and parasite genomic DNA. Parasite genomic DNA was only
available for 79 of the 179 acute patient visits. Therefore, the sample size for
this descriptive study was 79 participants. Although it would have been prudent
to examine the antibody response of study participants from their acute visit
through their convalescent visit, there were not enough study participants within
the first 79 patients to return for their convalescent visit. There was no parasite
genomic DNA provided for the repeat-acute responders, leaving no method of
comparing the prominent DBPII variant between visits.

Because of these

obstacles, immune response over time could not be adequately analyzed.
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2.0 Association Between DBPII Variants and Antibody Response
2.1

DBPII Variants.

Variations in DBPII were measured using the

evolutionary distance from DBPII-Sal 1, the first variant of P. vivax to be
sequenced. Since DBPII is a highly conserved protein with limited polymorphic
sites, the evolutionary distance is used to measure the polymorphic differences
between the Cambodian parasite isolates and Sal 1. However, because of the
highly conserved nature of DBPII, the evolutionary distances were very small
numbers with little variation. This very small difference in exposure could’ve
reduced the power of the analysis because a large sample size is needed to
detect very small differences.

For future studies it might be constructive to

transform the evolutionary distance in a meaningful way to analyze a larger
exposure difference.
DBPII-Sal was the most prevalent variant to infect the study participants,
with 30% of parasite isolates having the same amino acid sequence and 6% of
parasite isolates having a one amino acid difference from DBPII-Sal 1. None of
the Cambodian variants or the test variants differed completely from Sal 1,
although DBPII-P differs from DBPII-Sal 1 in every major polymorphic site except
the glutamic acid at site 371. Although it has been shown biologically that one
amino acid can change an individual’s immune and inhibitory response to P.
vivax, the one amino acid difference is too small to measure and analyze
appropriately through logistic regression without a very large sample.
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2.2

Antibody Binding Affinity. The Pursat, Cambodia Collection Study

recruited and enrolled only those individuals with clinical symptoms of malaria.
Therefore, antibody binding affinity to DBPII variants could be used to measure
the how much malaria illness is due to a particulate variant in the study
population. The degree of illness was, in many ways, self –reported by study
participants and was found to be unreliable information. The antibody binding
affinity was a method of measuring the immune response to a DBPII variant and
could potentially provide information about the, which DBP epitopes the
antibodies were binding.
The antibody response couldn’t be categorized because of the low
sample size and the minute differences within the exposure variables. Therefore,
a continuous antibody response was used to measure the immune response to
the test variants. Once adjusted for parasitemia, there was a very small percent
decrease in the antibody binding affinity to DBPII-Sal 1as the evolutionary
distance moved further away from DBPII-Sal 1.

This means that as more

polymorphic amino acids varied from those found in DBPII-Sal 1, the antibody
binding affinity to DBPII-Sal 1 decreased slightly.

This decrease was to be

expected because 30% of the Cambodian samples were the same as DBPII-Sal
1. No such significant drop was seen in the other DBPII test variants. One
possible explanation is that the evolutionary distance was measured from DBPIISal 1 only and not from each individual test variant.

To have a better

understanding of whether the test variants bind human antibodies similar to the
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Cambodian variants, it might be useful to analyze this relationship with the
evolutionary distances from each test variant and not just DBPII-Sal 1.
2.3

Confounding.

Throughout the analysis it was difficult to identify

confounding variables. It was initially thought that age and gender could be to
potential confounders to the analysis.

Studies in PNG, where malaria is

endemic, show that very young patients become ill with P. vivax infections and
produce a long-term immunity as they age (Xainli et al., 2002).

Continuous

exposure to mosquitoes allows for exposure to multiple P. vivax variants at a
young age, leading to asymptomatic malaria infections or immunity.

This

continuous exposure is not always the case in Pursat, Cambodia. Mosquitoes
are most prevalent in the forest region of the country, including Veal Vang and
parts of Kravanh known as the forest fringe. In addition, mosquitoes are more
prevalent during the rainy season in the forest. It is unclear how long the rainy
season lasts or if malaria infections are persistent year round in the forest. The
lack of exposure means that all age levels are vulnerable to malaria infections
and there is no prospect of age-defined immunity.
It was also hypothesized that gender may be a confounder because
malaria in Cambodia can be seen as a work related illness. Workers from the
four non-forest districts travel to the forest for mining, agriculture, and other
occupations. It was initially thought that male workers would enter the forest to
work and come home with malaria; however, men who have to leave for
extended periods of time will often take their families with them. Also, families
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with children live in the forest and along the forest fringe and are exposure to
malaria more often. Neither age nor gender were found as confounders during
the analysis.
Parasitemia and location of the patient were the only confounders in the
study. Parasitemia was measured in parasite per microliter, meaning the number
of parasite in a microliter of blood. This is calculated by counting the number of
parasite per leucocytes in a thin blood smear. Parasitemia seemed to mask the
relationship

between

the

evolutionary

distance

and

antibody

binding.

Parasitemia is not in the casual pathway between the parasite variant and the
antibody response.

Antibodies will be from regardless of the parasitemia;

however, a higher parasitemia may provide more epitopes for binding.

It is

unclear whether parasitemia is unclear whether one variant is more virulent than
another variant; however, it paraistemia could have been influenced by the most
predominant variant in Cambodia, DBPII-Sal 1.

As the parasitemia and the

evolutionary distance from DBPII-Sal increased, the antibody binding decreased.
The variable “location” pertains to the location of the patient at the time of
diagnosis, whether along the road in Pursat or at the provincial clinic. Location
could have been a source of slight confounding to the point-biserial correlation,
describing the relationship between specific amino acid changes and antibody
binding affinity. Once adjusted for in the partial correlation model, the strength of
the correlation increased slightly. The location of the participant could be related
to the DBPII variant by location.

Individuals collected from the road were
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probably from parts of Veal Vang and Kravanh, meaning that they may have a
different duration of exposure than those in the non-forest districts. The location
could be connected with antibody binding affinity because people from the forest
regions may be exposure to more variants, thereby making antibodies to multiple
variants at a time. There was only slight masking of the relationship between
exposure and outcome.

70

3.0 Specific Amino Acids Correlated to Antibody Response
The point-biserial correlation matrix was used to determine if there was a
relationship between specific amino acids polymorphisms and antibody binding
affinity. This was an effort to statistically map the polymorphic alleles responsible
for specific antibody responses. Since the amino acid sequences were mapped
using DBPII-Sal 1 as a control sequence, all amino acid differences were in
reference to DBPII-Sal 1. Although having a high antibody response to DBPIIAH was not correlated to having a high antibody response to any other variant
and the K371E amino acid substitution is the only polymorphic difference
between DBPII-7.18 and AH, this amino acid substitution wasn’t statistically
correlated to higher antibody response.

It was presumed there would be a

difference in antibody binding to DBPII-AH correlated to the amino acid
difference at K371E (DBPII-Sal 1 has the same lysine as DBPII-7.18). However,
no such correlation exists.
There was a weak to moderate correlation between antibody binding to
each of the variants and sites 384 and 437. Site 384 is part of the DEK region of
DBP and is the most polymorphic site in region II. Also, were many polymorphic
residues in DBPII are dimorphic, the DEK region is known to have multiple
polymorphic substitutions, potentially due to high immune pressure on this
region.

The W437R amino acid substitution, a tryptophan to an arginine

substitution, has also been shown to be important in blocking inhibitory
antibodies from binding to the DBP active site. Although there is no difference in
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these amino acids between DBPII-7.18 and Ah, there is a difference between
them and DBPII-Sal 1. This may account for the low correlation between them.
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4.0 Further Research
4.1 Thesis Summary. This was a preliminary study of the first year of sera
collection from the P. vivax Collection Study. The purpose of this study was to
characterize the immune response against P. vivax malaria infections in a
seasonally endemic region. It was hypothesized the immune response to DBPII
variants in Pursat, Cambodia would follow a strain specific pattern, making it
possible to determine a particular variant most responsible for clinical illness.
The main exposure was to a particular DBPII variant and the outcome was the
antibody response to a wide-array of recombinant DBPII variants, helping to
determine if antibodies were binding to a polymorphic or conserved epitope.
Based on the results, variants similar to DBPII-Sal 1 tend to bind more strongly to
that recombinant protein than to any other recombinant protein.

This would

imply that a variant very similar to or the same as, DBPII-Sal 1 is responsible for
the majority of clinical illness in the study. However, these results are based on
the evolutionary distance from DBPII-Sal 1. Further analysis may show that,
given another control amino acid sequence, another variant could be more
responsible for clinical illness.

Also, there was no parasite genomic DNA

provided for the repeat-acute sera to determine if individuals were getting
reinfected with the same or a different DBPII variant. Although the data would
suggest that DBPII-Sal 1 is responsible for the burden of clinical illness, the
information provided made it difficult to make a decisive determination.
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It was also believed the polymorphic substitutions could be statistically
mapped as they correlate to the antibody binding affinity to the five variants. This
was aimed at providing researchers a guide when determining which amino acid
substitution should be focused on to identify inhibitory antibodies. Amino acid
differences between DBPII-AH and DBPII-Sal1 were thought to be responsible
for the strain-specific immune response by DBPII-AH, in particular the K371E
substitution. This was not possible to determine since the analysis only provided
weak correlations.
4.2 Additional Analysis. This study was unable to confidently identify the
DBPII variant responsible for clinical disease nor the polymorphic residue
responsible the immune response.

Additional studies of the sera from

subsequent years of the study may provide this information.

More than 79

participants are needed to make a more definitive characterization about variants
in Pursat.
This study also focused on the parasites interactions with the host and little
on the genetic human host determinants of disease. As the questioning process
improves between the Pursat researchers and the patients, it would be
interesting to explore the antibody response and its connection with th e clinical
symptoms

ofdisease.
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